Correlation between MYH9 and lymph node metastasis indicated that MYH9 can be regarded as a potential therapy target, providing a foundation for clinical diagnosis and molecular therapy in ESCC patients. This evidence concerns the gene MYH9 and esophageal squamous cell carcinoma.